

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 291 430 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

12.03.2003 Bulletin 2003/11

(21) Application number: 01936941.2

(22) Date of filing: 11.06.2001

(51) Int Cl.7: **C12N 15/54, C12N 9/12,**

C12N 1/21, C12Q 1/48,

C07K 16/40, A61K 31/7125,

A61K 48/00, A61P 3/04,

A61P 3/10, A61P 7/00,

A61P 25/00, A61P 29/00,

A61P 31/18, A61P 35/00

(86) International application number:

PCT/JP01/04889

(87) International publication number:

WO 01/098575 (20.12.2001 Gazette 2001/51)

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: 14.06.2000 JP 2000178039

(71) Applicant: **Sankyo Company, Limited**
Tokyo 103-8426 (JP)

(72) Inventors:

- **SUGIURA, Masako,**
c/o SANKYO COMPANY, LIMITED
Tokyo 140-8710 (JP)

• **KONO, Kenta, c/o SANKYO COMPANY, LIMITED**
Tokyo 140-8710 (JP)

• **KOHAMA, Takafumi,**
c/o SANKYO COMPANY, LIMITED
Tokyo 140-8710 (JP)

(74) Representative: **Gibson, Christian John Robert**
MARKS & CLERK,
57/60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(54) CERAMIDE KINASE AND DNA ENCODING THE SAME

(57) The present invention provides a novel protein having ceramide kinase activity which can be a target for a prophylactic or therapeutic medicament against neuronal disease, inflammation, HIV infection, type 2 diabetes mellitus, obesity, septicemia, arteriosclerosis and cancer.

Specifically, a protein which comprises an amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing, a DNA which encodes the protein, a recombinant vector comprising the DNA, a host cell transformed with the recombinant vector, a method for producing the protein, and utilities

of the protein are provided.

By using the method of the present invention, a novel compound is provided having a specifically activating or inhibiting activity to ceramide kinase and useful as a medicament for treating neuronal disorder, an anti-inflammatory medicament, a medicament for treating HIV infection, an anti-type 2 diabetes mellitus medicament, an anti-obesity medicament, an anti-septicemia medicament, an anti-arteriosclerosis medicament, and an anticancer medicament.

EP 1 291 430 A1

Description**[Field of the Invention]**

5 **[0001]** The present invention relates to a novel protein having ceramide kinase activity which may be a target of a medicament preventing or treating neuronal disease, inflammation, HIV infection, type 2 diabetes mellitus, obesity, septicemia, arteriosclerosis and cancer, DNA which encodes the protein, a recombinant DNA vector comprising the DNA, a host transformed with the recombinant DNA vector, a method for producing the ceramide kinase, and use of the protein.

[Background of the Invention]

15 **[0002]** Sphingolipids have been conventionally considered to be one of the major components of cell membrane as glycerophospholipids and cholesterol. It has been known that glycerophospholipids not only maintain cell membrane structure but also let the cells produce a lot of physiologically active substances as metabolites thereof. However, a physiological activity of sphingolipid metabolites has been hardly known until recently. In these years, physiological activities of some sphingolipid metabolites such as induction of apoptosis and cell proliferation-stimulating activity, have come to be known, and the possibility that enzymes metabolizing sphingolipid closely participate in physiological reactions or various diseases has been suggested. Especially, ceramide attracts attention as a regulator which controls a lot of cell mechanisms (See Hannun, Y.A. and Obeid, L.M. (1995) TIBS 20, 73-77).

20 **[0003]** For example, it is known that ceramide functions as a second messenger of inflammatory cytokines, such as TNF- α and IL-1 β , and activates arachidonic acid pathways such as phospholipase A₂ and the like (See Spiegel, S. et al. (1996) Curr. Opin. Cell Biol. 8, 159-167 and Mathias S. et al., (1993) Science 259, 519-522). That is, ceramide can be considered to be an exacerbating factor in various inflammatory disorders. Moreover, it has also been reported that ceramide functions as an exacerbating factor in reduction of CD4⁺ T cell accompanied by apoptosis and HIV infection of brain cells in patients infected with HIV (See Coline, M. G et al. (1997) Proc. Assoc. Am. Physicians 109, 148-153 and Wilt, S. et al. (1995) Ann. Neurol. 37, 381-394). Furthermore, it is known that TNF- α causes insulin resistance in type 2 diabetes mellitus and obesity, and it is thought that ceramide functions as an exacerbating factor also on the downstream thereof (See Begum, N. et al. (1996) Eur. J. Biochem. 238, 214-220 and Hotamisligil, G S. et al. (1996) Science 271, 665 to 668). Moreover, it has also been reported that ceramide functions as a second messenger in septicemia caused by lipopolysaccharide (LPS) or the like as a trigger (see Beutler, B. and Kruys, V. (1995) J. Cardiovasc. Pharmacol. 25, S1-S8). Furthermore, it has also been reported that increase of ceramide accompanied by the activation of sphingomyelinase functions as an exacerbating factor in the aggregating reaction of LDL which is to be a trigger of arteriosclerosis lesions (See Schissel, S. L. et al. (1996) J. Clin. Invest. 98, 1455-1464).

35 **[0004]** On the contrary, it is known that ceramide promotes apoptosis of cancer cells in radiotherapy and chemotherapy for cancer treatments (See Michael, J. M. et al. (1997) Cancer Res. 57, 3600-3605 and Bose, R. et al. (1995) Cell 82, 405-414 and Jaffrezou, J. P. et al. (1996) EMBO J. 15, 2417-2424).

40 **[0005]** On the other hand, some physiological activities are known also about ceramide-1-phosphate, a metabolite of ceramide and ceramide kinase, a ceramide-1-phosphate-producing enzyme. For example, ceramide-1-phosphate produced through the activation of ceramide kinase responding to calcium stimulus regulates the release of neuronal transmitters from brain synapses (Bajjalieh, S. M. et al. (1989) J. Biol. Chem. 264, 14354-14360 and Shinghal, R. et al. (1993) J. Neurochem. 61, 2279-2285). Therefore, it may be possible to treat various neuronal disorders including Alzheimer's disease by regulating the activity of ceramide kinase with a medicament or the like. Moreover, it is considered that ceramide-1-phosphate has an activity to block the various mechanisms of ceramides mentioned above (See Dressler, K. A. et al. (1990) J. Biol. Chem. 265, 14917-14921). That is, it is thought that the disorders to which ceramide acts as an exacerbating factor, including various inflammatory disorders such as chronic arthritis, HIV infection, and type 2 diabetes mellitus caused by insulin resistance as a trigger, obesity, septicemia and arteriosclerosis, can be suppressed by using ceramide-1-phosphate. Therefore, it can be a method for treating various inflammatory disorders, HIV infection, type 2 diabetes, obesity, septicemia, arteriosclerosis and the like to activate ceramide kinase with a medicament or the like. On the contrary, in the radiotherapy and chemotherapy of cancer, the amount of ceramide can be maintained and the therapeutic efficacy can be improved by inhibiting ceramide kinase activity.

50 **[0006]** Moreover, quantification of ceramide is considered to be important for analyzing the condition of various diseases for the above-mentioned reasons. By using ceramide kinase, it is possible to provide a simple, specific and highly sensitive method for quantifying the ceramide content in a cell or a tissue. Although a lot of methods such as mass spectrometry and HPLC are known as methods for quantifying ceramide, there are problems in sensitivity or simplicity. While a method using diacylglycerol kinase is also known (See Van Veldhoven, P. P. et al. (1995) Biochem. Mol. Biol. Int. 36, 21-30), said enzyme is an enzyme which essentially phosphorylates diacylglycerol, and is not sufficient in its specificity and specific activity for ceramide. Therefore, a specific and sensitive method for quantifying or detecting

ceramide can be established by using ceramide kinase.

[0007] However, there is no report wherein the ceramide kinase which is an enzyme for producing ceramide-1-phosphate is purified or cloned, and many of its details have remained unknown. Then, it has been desired to clone the ceramide kinase gene and express the protein encoded thereby, so that it may be preferably used for screening a therapeutic or prophylactic medicament for the various above-mentioned disorders.

[0008] In addition, an expressed sequence tag (hereinafter referred to as "EST") corresponding to a part of the DNA which encodes the protein of the present invention is known, when a homology search is performed by using the dbEST database of NCBI (National Center for Biotechnology Information, U.S.A.) based on the sequence of known mouse sphingosine kinase. However, there is no specific suggestion regarding the function of the protein of the present invention in said EST data.

[0009] That is, the purpose of the present invention is to clone the gene encoding a novel ceramide kinase which exists in a human, to provide a novel method for screening a candidate substance as a medicament for treating neuronal disorders, an anti-inflammatory medicament, a medicament for treating the HIV infection, an anti-type 2 diabetes mellitus medicament, an anti-obesity medicament, a medicament for treating septicemia, an anti-arteriosclerosis medicament and an anticancer medicament thereby, and to provide a method for analyzing various conditions of the disorders. Such a search for candidate substances as a novel type of medicament is performed by screening substances which activate or inhibit the ceramide kinase activity of the protein of the present invention. The analysis of various conditions of the disorders can be performed by labeling ceramides in various samples with the protein of the present invention.

[Disclosure of the invention]

[0010] The inventors of the present invention cloned cDNA which encodes a novel protein which is partially homologous to mouse sphingosine kinase, and determined successfully the primary structure of the full length novel protein. Furthermore, they successfully allowed the novel protein to be expressed, and confirmed that the novel protein has ceramide kinase activity. Thereby, the present invention was completed.

[0011] First, the present invention relates to a protein described in any one of the following (i) to (iii):

- (i) a protein which comprises an amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing;
- (ii) a protein which comprises an amino acid sequence wherein one or more than one amino acids are added, deleted and/or replaced in the amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing, and has ceramide kinase activity;
- (iii) a protein encoded by DNA which is inserted in the plasmid carried by a transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184).

[0012] Secondly, the present invention relates to DNA which encodes the above-mentioned protein. Such DNA of the present invention is preferably DNA comprising a nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing; DNA which hybridizes with the DNA which comprises a nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing under stringent conditions, and encodes a protein having ceramide kinase activity; or DNA inserted in the plasmid which is carried by transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184). However, the present invention is not limited thereto, but includes all the DNAs having the nucleotide sequence which encodes the above-mentioned protein.

[0013] Thirdly, the present invention relates to a recombinant DNA vector comprising the above-mentioned DNA. While the preferable recombinant DNA vector of the present invention is pCR3.1-CERK1, a recombinant DNA vector, which is carried by transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184), or a recombinant DNA vector which is an expression vector, the present invention is not limited thereto.

[0014] Fourthly, the present invention relates to a host cell transformed with the above-mentioned recombinant DNA vector. Such a host cell of the present invention is preferably transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184), or a host cell transformed with the recombinant DNA vector which is an expression vector of the present invention, but the present invention is not limited thereto.

[0015] Fifthly, the present invention relates to a method for producing the above-mentioned protein. One example thereof is one based on a genetic engineering procedure wherein the host cell transformed with the above-mentioned expression vector is cultured under conditions wherein the protein having ceramide kinase activity can be produced, and subsequently a protein having ceramide kinase activity is collected from the culture.

[0016] Another example of the method for producing the protein of the present invention is based on a biochemical procedure which comprises the following steps (i) to (iii):

- (i) an extract of a material containing a protein according to any one of (i) to (iii) dissolved in a solvent which does

not contain calmodulin is allowed to adsorb on affinity-chromatography resin having calmodulin as a substituent;
 (ii) the resin of (i) is washed with the solvent which does not contain calmodulin;
 (iii) a protein having ceramide kinase activity is eluted with a solvent containing ethylene glycol bis (β -aminoethyl
 ether)- N,N,N',N'-tetraacetic acid (EGTA) or ethylenediaminetetraacetic acid (EDTA) from the resin washed in the
 step (ii).

[0017] Sixthly, the present invention relates to a method for testing the ceramide kinase-activating or inhibiting activity of a compound or a composition wherein the above-mentioned protein, a substrate which can be specifically phosphorylated by the protein, and the compound or the composition sample are allowed to coexist, and then the amount of the substrate phosphorylated by the protein is measured, and the resulting amount is compared with that without addition of the compound or the composition sample thereto.


[0018] Seventhly, the present invention relates to a method for detecting or quantifying ceramide in a sample wherein the above-mentioned protein, the sample to be tested, and labeled adenosine 5'-triphosphate (hereinafter referred to as "ATP") are allowed to coexist and then the labeled ceramide is detected or quantified.

[0019] Eighthly, the present invention relates to an antibody which specifically binds to the above-mentioned protein which is a novel protein.

[0020] That is, the present invention provides a novel protein, DNA which encodes the protein, a recombinant vector comprising the DNA, a host cell transformed with the vector, a method for producing the protein, use of the protein, and an antibody specifically binding to the protein.

[0021] In the present invention, the word "ceramide kinase activity" means an activity to phosphorylate the hydroxyl group at the 1-position of various ceramides such as the N-acetyl form of D-erythro-sphingosine (hereinafter referred to as "C₂-ceramide"), the N-hexanoyl form of D-erythro-sphingosine (hereinafter referred to as "C₆-ceramide"), the N-octanoyl form of D-erythro sphingosine (hereinafter referred to as "C₈-ceramide"), the N-palmitoyl form of D-erythro-sphingosine (hereinafter referred to as "C₁₆-ceramide"), and ceramide derived from bovine fetal brain, and various optical isomers thereof, resulting in the production of ceramide-1-phosphate. Namely, it means an activity for catalyzing a reaction shown by the following formula:

[Compound 1]



wherein R represents CH₃ (in the case of C₂-ceramide), C₅H₁₁ (in the case of C₆-ceramide), C₇H₁₅ (in the case of C₈-ceramide), C₁₅H₃₁ (in the case of C₁₆-ceramide), C₁₇H₃₅ (in the case of C₁₈-ceramide), or the like. Moreover, the preferable substrates which can be phosphorylated by the ceramide kinase activity possessed by the protein of the present invention are various ceramides such as C₂-ceramide, C₆-ceramide, C₈-ceramide, C₁₆-ceramide, and a ceramide derived from bovine fetal brain (mainly containing C₁₈-ceramide) and the various optical isomers thereof, and

more preferably C₆-ceramides, but not limited thereto.

[0022] DNA which encodes the protein of the present invention can be obtained by a method well known to the skilled person in the art of the present invention, for example, by preparing mRNA from the cultured cells which expresses the protein, then synthesizing cDNA using it as a template, and screening cDNA which encodes the protein of the present invention by a well-known method, or the like.

[0023] More specifically, for instance, part or all of the DNA which encodes the protein of the present invention can be obtained by preparing a probe based on the full sequence or a partial sequence of cDNA of mouse sphingosine kinase, and analyzing the sequence of the clones obtained from a cDNA library derived from mammals by performing a colony-hybridization method under the conditions of low stringency, and selecting the clone having a sequence highly homologous to the nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing. Moreover, a part of the DNA which encodes the protein of the present invention can be obtained also by preparing primers based on the known sequence of mouse sphingosine kinase (preferably primers are prepared based on the sequence of the conserved region in phylogeny), and performing a polymerase chain reaction (hereinafter referred to as "PCR", see Salki R. K. et al. (1988) Science 239, 487 to 491) using the cDNA library derived from mammals as a template, or performing reverse-transcriptase polymerase chain reaction (hereinafter referred to as "RT-PCR") using mRNA derived from mammals as a template, and analyzing the resultant sequence the product has and selecting the clone having a sequence which is highly homologous to the nucleotide sequences shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing.

[0024] Furthermore, full length cDNA which encodes the protein of the present invention can be obtained, for example, by preparing a probe based on the partial sequence obtained as mentioned above, and analyzing the sequence of the clone obtained by conducting colony-hybridization under stringent conditions over the cDNA library derived from mammals, or by preparing a probe based on the partial sequence, and performing PCR using the cDNA library derived from mammals as a template or RT-PCR using mRNA derived from mammals as a template, and then analyzing the sequence of the product, and furthermore performing the rapid amplification of cDNA ends (hereinafter referred to as "RACE". See Jikken-Igaku, (1994), 12 (8), 35-38) if necessary, using a primer based on a partial sequence and mRNA derived from mammals or using commercially available kit and a commercially available cDNA library.

[0025] An animal cell used as a source of the mRNA is preferably human embryo kidney cell HEK293 (ATCC CRL-1573), but cells or tissues derived from mammals, or the other cultured-cell strains (including those of human origin) can also be used.

[0026] Extraction of mRNA can be performed by the guanidinium - cesium chloride ultracentrifugation method, the guanidinium thiocyanate-hot phenol method, the guanidinium thiocyanate - HCl method, the acidic guanidinium thiocyanate - phenol-chloroform method, but a commercially available mRNA separation kit can also be used.

[0027] Since it is known that many mRNAs existing in the cytoplasm of a eukaryotic cell have a poly (A) sequence at the 3'-end thereof, mRNA can be adsorbed on a biotinized oligo (dT) probe on the basis of this property, and purified by catching mRNA to the paramagnetic grain wherein streptavidin is fixed by using the binding between biotin and streptavidin, and eluting the mRNA after a washing operation. Moreover, mRNA can also be further fractionated by the sucrose density gradient centrifugation method or the like.

[0028] In order to confirm that the mRNA obtained as described above encodes a protein having a ceramide kinase activity, mRNA can be translated into protein, and the enzyme activity thereof can be examined. Alternatively, a method for identifying the protein with an antibody specific to the protein can be used. For example, mRNA is injected into an oocyte of a *Xenopus* (*Xenopus laevis*), and can be translated (Gardon J. B. et al. (1972) Nature 233, 177-182). Alternatively, non-cell translation systems, such as a rabbit reticulocyte system and a wheat-germ system, can also be used (Schleif, R. F. and Wensink, P. C. (1981): "Practical Methods in Molecular Biology", Springer-Verlag, and NY).

[0029] Moreover, after synthesizing a single stranded cDNA by using mRNA obtained by the above-mentioned method as a template and reverse transcriptase, a double stranded cDNA is prepared from this single stranded cDNA. It can be conducted by a method such as the S1 nuclease method (Efstratiadis, A. et al. (1978) Cell 7, 279-288), the Land method (Land, H. et al. (1981) Nucleic Acids Res. 9, 2251-2266), the O. Joon Yoo method (Yoo, O. J. et al. (1983) Proc. Natl. Acad. Sci. USA 79, 1049-1053) or the like. However, the Okayama-Berg method (Okayama, H. and Berg, P. (1982) Mol. Cell. Biol. 2, 161-170) is preferable for the purpose of the present invention.

[0030] Then, a recombinant phage having a cDNA fragment can be stably maintained and amplified by incorporating the resultant cDNA fragment into a lambda phage vector and allowing it to self-replicate. For example, when lambda phage λ ZAPII (manufactured by Stratagene corporation) is used, *Escherichia coli* XL1-Blue MRF or JM 109 is allowed to make a plaque. The recombinant can be selected based on the existence of coloring due to the metabolism of 5-Bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-gal) in the plaques. As a vector, not only the lambda phage vector but also a plasmid vector can be used.

[0031] Moreover, various commercially available cDNA libraries (for example, manufactured by Clontech corporation) can also be used. As a method for selecting a clone which has a cDNA encoding the desired protein which has a ceramide kinase activity from the library obtained as mentioned above, any one of the various methods as shown

below, for example, can be employed.

(1) A screening method using a synthetic oligonucleotide probe

[0032] If the amino acid sequence of the full length or part of the desired protein has been elucidated (the sequence can be that in any region of the protein, as long as it is specific and containing continuous amino acids), oligonucleotides corresponding thereto may be synthesized (For an amino acid having codon degeneracy, a codon which is highly frequent in the host can be used, or any possible codons corresponded to said amino acid can be used to synthesize the mixture of more than one nucleotides. In the latter case, the number of oligonucleotides to be used can be reduced by incorporating inosine thereto), and used as a probe after being labeled with ^{32}P , ^{35}S , biotin or the like, hybridizing with recombinant phage DNA immobilized on a nitrocellulose or a nylon filter to search and select a positive clone.

(2) A screening method using the probe prepared by polymerase chain reaction

[0033] When the amino acid sequence of the full length or part of the desired protein has been elucidated, an oligonucleotide of the antisense strand chain corresponding to a part of the C terminus thereof is synthesized as well as the sense strand chain corresponding to a part of the amino terminus thereof, and PCR is performed, and then a DNA fragment which encodes the desired protein is amplified. The cDNA synthesized by reverse transcriptase reaction of mRNA derived from a cell producing the protein of the present invention or the genomic DNA can be used as a template of the reaction. Thus, the prepared DNA fragment is labeled with ^{32}P , ^{35}S , or biotin, and the cDNA library or the genomic library was screened by plaque hybridization or colony hybridization using the DNA fragment as a probe, and the desired clone is selected.

(3) A screening method by letting another animal cell strain produce the protein which has ceramide kinase activity:

[0034] An animal host cell is transformed with a plasmid (a plasmid which is self-replicable and contains transcription promoter region, or which is integrated into the chromosome of an animal cell) which is an expression vector wherein the obtained cDNA as mentioned above is inserted, and is allowed to produce the protein encoded by the cDNA. A strain which has a cDNA encoding the protein of the present invention is selected by measuring ceramide kinase activity in the conditioned medium of the cell culture or the extract of the cell, or by detecting the existence of the protein of the present invention using an antibody that specifically binds to the protein of the present invention and a second antibody to said antibody. Conventional cells such as COS and CHO can be used as an animal host cell. However, for detecting the protein of the present invention as an exogenous gene product more easily, it is preferable that the host cell itself does not produce the protein of the present invention under a regular culture condition.

(4) A method using the system of selective hybridization translation:

[0035] The cDNA obtainable from the transformant is blotted on a nitrocellulose filter or nylon filter, and mRNA extracted from tissues or cells having an ability to produce the protein of the present invention are allowed to hybridize thereto, and then mRNA hybridizing to the cDNA is dissociated and collected. The collected mRNA is translated into protein by using a protein translation system (for example, injection into an oocyte of a *Xenopus*, or a cell free system such as a rabbit reticulocyte lysate and wheat germ system), and the ceramide kinase activity of the protein is examined, or the protein is detected by using an antibody to the protein having ceramide kinase activity, to select the desired strain.

[0036] Harvest of DNA encoding the protein of the present invention from the desired transformant which is obtained as mentioned above can be performed by known techniques (Maniatis, T., et al., in "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY, (1982)). For example, the region corresponding to the cDNA can be cut out from plasmid DNA after separating the fraction corresponding to the plasmid DNA from the cells.

[0037] Moreover, the gene which encodes the protein of the present invention can also be obtained preferably by the DNA/RNA amplifying method according to PCR method. Especially when full length cDNA can not be obtained from a library, the full length of the cDNA containing the both ends can be obtained by the above-mentioned RACE. The primer used for said PCR method can be suitably designed on the basis of the sequence information of the gene of the present invention, and can be synthesized according to conventional methods.

[0038] DNA thus obtained may be sequenced by, for example, Maxam-Gilbert's chemical modification technique [cf. Maxam, A. M. and Gilbert, W. (1980) in "Methods in Enzymology" 65, 499-576], the dideoxy chain termination method using M13 phage [cf. Messing J. and Vieira J. (1982) Gene, 19, 269-276] or the like.

[0039] Moreover, automatic DNA sequence analyzers (for example, the model 373A manufactured by Perkin Elmer Japan Applied Biosystems) or the like, utilizing fluorochromes instead of radio-isotopes, can also be used.

[0040] The transformed *Escherichia coli* strain E.coli pCR3.1-CERK1 SANK 70300 carrying the plasmid wherein the

cDNA encoding the most preferable protein of the present invention is inserted was deposited internationally on June 2, 2000 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology at 1-1-3, Higashi-cho, Tsukuba-shi, Ibaraki-ken, Japan, and was accorded the deposition number FERM BP-7184. Therefore, the gene which encodes the protein of the present invention is obtainable from said strain.

[0041] A fragment containing a gene which encodes the protein of the present invention cloned as described above can be inserted into a vector DNA, and used for the transformation of other prokaryotic host cells or eukaryotic host cells. The gene can be expressed in each host cell by introducing a suitable promoter and sequences regarding the expression of phenotype thereinto.

[0042] Suitable prokaryotic host cells include, for example, *E. coli* (*Escherichia coli*), *Bacillus subtilis*, and the like. In order to express the desired gene in such host cells, these host cells can be transformed with a plasmid vector containing a replicon, an origin for replication, derived from a species compatible with the host and regulatory sequences. These vectors preferably have sequences capable of giving selectivity of the phenotype to the transformed cell.

[0043] For example, K12 strain can be conventionally used as *E. coli*. Suitable vectors include pBR322 and the pUC-derived plasmids can be used, without being limited thereto. Other known strains and vectors can also be utilized.

[0044] Suitable promoters include the tryptophan promoter (*trp*), the lactose promoter (*lac*), the tryptophan lactose promoter (*tac*), the lipoprotein promoter (*lpp*), and the polypeptide chain elongation factor Tu promoter (*tufB*) can be used for producing the protein of the present invention, without being limited thereto.

[0045] A preferred strain of *Bacillus subtilis* is 207-25 strain, and a preferred vector is pTUB228 [cf. Ohmura, K., et al., (1984), *J. Biochem.*, 95, 87-93], without being limited thereto.

[0046] If the DNA sequence encoding the signal peptide sequence of *Bacillus subtilis* α -amylase is linked to the DNA of the present invention, it becomes possible to express the protein of the present invention outside the cells via the secretion thereof.

[0047] Examples of the eukaryotic host cells include vertebrate cells, insect cells, and yeasts or the like. Examples of vertebrate cells include: COS cells (Gluzman, Y. (1981) *Cell* 23, 175-182, ATCC CRL-1650) which are cells derived from an ape, a dihydrofolate reductase-deficient strain of Chinese hamster ovary cells (CHO cell, ATCC CCL-61), or the like, but it is not limited thereto (Urtaub, G. and Chasin, L.A. (1980) *Proc. Natl. Acad. Sci. USA* 77, 4126-4220).

[0048] As expression promoters for vertebrate cells, those comprising: a promoter which is usually located in the upstream region of a gene to be expressed; a splicing site of RNA; a polyadenylation site; and a transcriptional termination sequence can be used. It can also comprise an origin of replication if necessary. An example of said expression vector is pSV2dhfr containing the SV40 early promoter (Subramani, S., et al. (1981), *Mol. Cell. Bio.*, 1, 854-864), without being limited thereto.

[0049] When COS cells are used as host cells, expression vectors suitably comprise the SV40 replication origin which enables the cell to self-replicate, a transcription promoter, a transcription termination signal and an RNA splicing site. The expression vectors can be used to transform COS cells by a method, such as the diamino ethyl (DEAE)-dextran method [cf. Luthman, H. and Magnusson, G. (1983), *Nucleic Acids Res.*, 11, 1295-1308], the calcium phosphate-DNA co-precipitation method [Graham, F. L. and Van der Eb, A. J., (1973), *Virology*, 52, 456-457] and the electric pulse electroporation method [cf. Neumann, E., et al., (1982), *EMBO J.*, 1, 841-845] or the like, and then the desired host cell can be obtained. In the case that CHO cells are used as the host cells, the transformed cells stably producing the protein of the present invention can be obtained by co-transfecting with an expression vector and a vector which can express the neo gene which functions as a marker for antibiotic G418-resistance, for example, PRSVneo (Sambrook, J. et al. (1989): "Molecular Cloning A Laboratory Manual" Cold Spring Harbor Laboratory, NY), pSV2-neo (Southern, P. J. and Berg, P. (1982) *J. Mol. Appl. Genet.* 1, 327-341) or the like, and selecting G-418 resistant colonies.

[0050] In the case that insect cells are used as host cells, established cells (Sf-9 or Sf-21) derived from ovarian-cells of *Spodoptera frugiperda* which belongs to *Lepidoptera Phalaenidae* and High Five cells derived from egg cells of *Trichopustian* (Wickham, T. J. et al. (1992) *Biotechnol. Prog.* 1: 391-396) or the like are conventionally used as host cells. The pVL1392/1393 utilizing the polyhedrin protein promoter of autographa polyhedron virus (AcNPV) is conventionally used as a baculovirus transfer vector (Kidd, I. M. and V. C. Emery (1993) The use of baculoviruses as expression vectors, *Applied Biochemistry and Biotechnology* 42, 137-159). Besides it, a vector utilizing a promoter of P10 or the basic protein of baculovirus is also available. Furthermore, it is possible to express recombinant protein as a secretory protein by joining the secretion-signal sequence of the envelope surface protein GP67 of AcNPV to the N-terminus of the desired protein (Zhe-mei Wang, et al. (1998) *Biol. Chem.*, 379, 167-174).

[0051] As an expression system using a eukaryotic microorganism as a host cell, yeast is generally well-known, and *Saccharomyces* yeasts, for example, baker's yeast, *Saccharomyces cerevisiae*, and petroleum yeast, *Pichia pastoris* are preferable. As an expression vector of eukaryotic microorganisms such as yeasts, the promoter of the alcohol dehydrogenase gene (Bennetzen, J. L. and Hall, B. D. (1982) *J. Biol. Chem.* 257, 3018-3025), the promoter of the acid-phosphatase gene (Miyahara, A. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80, 1-5), or the like can be used preferably. In order to express as a secreting protein, it is possible to be also expressed as a recombinant protein which has a secretion signal sequence and the cleavage site at the N-terminus thereof for an endogenous protease which

the host cell has or a known protease. For example, it is known that an active form of human mast cell tryptase, a trypsin-type serin protease, can be secreted into a medium by connecting the secretion signal sequence of the alpha factor derived from yeast and the cleavage site for KEX2 protease to the N-terminal part of the tryptase, and subsequently expressing in an expression system of petroleum yeast. (Andrew, L. Niles, et al. (1998) Biotechnol. Appl. Blochem. 28,125-131).

[0052] Transformants obtained by the above-mentioned methods can be cultured according to conventional methods, and thereby protein of the present invention can be produced either in or outside said transformants. Suitable culture media include various conventionally used media, depending on the host chosen. For example, for COS cells, there can be used RPMI-1840 and Dulbecco's Modified Eagle Medium (hereinafter referred to as DMEM), which can be supplemented with, if necessary, serum component such as fetal bovine serum.

[0053] The protein expressed as described above may be isolated and purified by various methods for separation according to the physical and chemical properties thereof (See "the biochemistry data book II", 1175 -1259, the 1st edition, 1st printing, June 23, 1980 published by Tokyokagakudojin; Biochemistry, vol.25, No.25, p8274-8277 (1986); and Eur.J.Biochem., 163, and P313-321 (1987)". For example, specific methods for separation include: common reconstruction treatment; treatment using protein precipitating-agents (salting out); centrifugation; osmotic shock method, freezing and melting method, ultrasonic lysis; various methods of chromatography such as ultrafiltration, gel filtration, adsorption chromatography, ion exchange chromatography, affinity chromatography and high performance liquid chromatography (HPLC), dialysis and combinations thereof.

[0054] Especially, since there is a sequence (the amino acid sequence shown in 422-435 of SEQ ID No. 2 of the Sequencing Listing) corresponding to a sequence motif known as the calmodulin binding sequence "the 1-8-14 motif type B (Rhoads, A.R. and Friedberg, F, The FASEB Journal 11, 331-340 reference)" in the amino acid sequence of the protein of the present invention, it is possible to allow a sample containing the protein of the present invention to adsorb on an affinity-chromatography resin which has calmodulin as a substituent (for example, calmodulin-Sepharose), and the resin is then washed with a solvent which does not contain calmodulin, followed by elution with a solvent containing EGTA or EDTA, to purify and collect the protein of the present invention efficiently.

[0055] Moreover, it can be purified efficiently in a nickel affinity column by connecting a histidine tag consisting of six residues to the recombinant protein to be expressed.

[0056] The protein of the present invention can be easily manufactured in large scale with high yield and high purity by combining the above-mentioned methods.

[0057] The amino acid sequence of the protein of the present invention purified as mentioned above can be confirmed by using automatic protein amino acid sequence analyzers (for example, Model 492 manufactured by Perkin Elmer Japan applied biosystems).

[0058] In order for the protein obtained from DNA of the present invention by the genetic engineering-procedure to exhibit ceramide kinase activity, it is not necessary for the protein to consist of a sequence which is completely the same as the amino acid sequence shown in the amino acid number 1-537 of SEQ ID No. 2 of the Sequencing Listing. For instance, a partial sequence thereof is also included in the protein of the present invention as long as it exhibits ceramide kinase activity. And, DNA encoding said protein is also included in the present invention.

[0059] In general, it is thought that genes of a eukaryotic organism can show polymorphism, as known for the interferon gene or the like. (See, for example, Nishi, T. et al. (1985) J. Biochem. 97, 153-159). As results of the polymorphism, one or more than one of the amino acids can be replaced in some cases. In other cases, a replacement in a nucleotide sequence may result in no change in the corresponding amino acid sequence. Many of the proteins wherein one or more amino acid residues are deleted, added, inserted or replaced in one or more than one positions in the protein of the present invention comprising an amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing, have a ceramide kinase activity (as an example showing that the protein which has the amino acid sequence wherein amino acids are replaced in the natural type amino acid sequence and which has an activity equivalent to natural type protein, it is known that a protein obtained on the basis of an Interleukin-2 (IL-2) gene wherein a nucleotide sequence corresponding to a cysteine thereof is replaced with that corresponding to serine keeps its IL-2 activity (Wang, A. et al. (1984) Science 224, 1431-1433)). All of these proteins are included in the present invention, as long as they have a ceramide kinase activity. DNA consisting of equivalent nucleotide sequences encoding these proteins is also included in the present invention.

[0060] Those various DNAs of the present invention can also be produced by chemical synthesis based on information of the above-mentioned protein having a ceramide kinase activity, according to a conventional method such as the phosphite triester method (Hunkapiller, M. et al. (1984) Nature 310, 105-111) or the like.

[0061] The selection of the codon corresponding to a desired amino acid can be done at random and, for example, it can be determined according to a conventional method, taking the frequency of codons in the host to be used into account (Grantham, R. et al. (1981) Nucleic Acids Res. 9, 143-174). Partial modification of the codon in the nucleotide sequence can be accomplished by site-directed mutagenesis utilizing synthetic oligonucleotide primers encoding the desired modifications [cf. Mark, D. F., et al., (1984), Proc. Natl. Acad. Sci. USA, 81, 5662-5666] or the like, by conven-

tional techniques. Constructing a mutant wherein one or more than one amino acids in an amino acid sequence are deleted may be performed, for example, in accordance with a method of deleting DNA from the terminal using exonuclease Bal31 or the like (Toshimitsu Kishimoto et al., "Zoku-Seikagaku Jikken Kouza 1, Idenshi-Kenkyu-hou II" 335-354), or the cassette mutagenesis method [cf. Toshimitsu Kishimoto, "Shin-Seikagaku Jikken Kouza 2: Kakusan III Kumikae DNA Gijutsu", 242-251].

[0062] The protein having ceramide kinase activity as described above is preferably those comprising 537 amino acids of an amino acid sequence shown in SEQ ID No. 2 of the Sequencing Listing wherein the amino terminus thereof is the methionine residue having the amino acid number 1.

[0063] Whether DNA can hybridize to DNA comprising the nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing can be determined, for example, by using a probe DNA which is labeled with (α - 32 P)dCTP or the like, according to the random primer method [cf. Feinberg, A. P. and Vogelstein, B. (1983), Anal. Biochem., 132, 6-13], or to the nick translation method [cf. Maniatis, T., et al., (1982), in "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY] or the like. DNA used for hybridization is adsorbed onto nitrocellulose or nylon membrane, and then fixed by heating or UV irradiation. The membrane is next soaked in prehybridisation solution containing 6 x SSC, 5% v/v Denhardt solution and 0.1% v/v sodium dodecyl sulphate (hereinafter referred to as SDS), and incubated at 55°C for 4 hours or more. Then, the probe previously prepared is dissolved in similar prehybridisation solution to a final specific activity of 1×10^6 cpm/ml, followed by incubation at 60°C overnight. Subsequently, the membrane is washed 5 times at 57°C for 5 minutes and further at 57°C for 20 minutes, and is then subjected to autoradiography. By using such a method, cDNA hybridizing to the DNA comprising the nucleotide sequence shown in the nucleotide numbers 124 to 1734 of SEQ ID No. 1 of the Sequencing Listing can be isolated from any cDNA library of various animal cells (Maniatis, T., et al., (1982), "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY).

[0064] As DNA which encodes the protein of the present invention above, DNA which comprises a nucleotide sequence shown in the nucleotide numbers 1 to 4463 of SEQ ID No. 1 of the Sequencing Listing is preferable, and DNA which comprises a nucleotide sequence shown in the nucleotide numbers 124 to 1734 of SEQ ID No. 1 of the Sequencing Listing is more preferable.

[0065] Whether the protein of the present invention has ceramide kinase activity can be confirmed according to the following method wherein the Spiegel method (See Olivera, A. and Spiegel, (1993) Nature 365, 557 to 560) for measuring sphingosine kinase activity using radioactive 32 P-ATP is modified.

[0066] Specifically, the solution containing the protein, HEPES buffer solution (pH 7.0) containing magnesium chloride, EDTA, dithiothreitol, sodium vanadate, and protease inhibitor (for example, Complete (trademark), manufactured by Boehringer Mannheim), C₆ ceramide dissolved in a substrate [bovine serum albumin (hereinafter referred to as "BSA") solution having a concentration of 4 mg/ml or ceramide micellized by using octyl glucoside (a preparation purified from bovine fetal brain, manufactured by Sigma), and radio-labeled 32 P-ATP are mixed and incubated at 37°C to perform a ceramide kinase reaction. Then, the reaction is stopped by adding 1N hydrochloric acid thereto and chloroform: methanol: concentrated hydrochloric acid (100:200:1 v/v) is added thereto and extracted. The resultant lower layer (chloroform phase) is developed on thin layer chromatography (hereinafter referred to as "TLC"), and analyzed. The ceramide kinase activity can be determined by quantifying the spot in said TLC corresponded to ceramide-1-phosphate (hereinafter referred to as "Cer-1-P") which is a product.

[0067] However, the method for detecting a ceramide kinase activity which the protein of the present invention has is not restricted thereto, but it is also possible to use other substrates which can be phosphorylated limitedly by the protein of the present invention (for example, 3 H-, 14 C- radio-labeled ceramide, or various fluorescent-labeled ceramides, or the like).

[0068] Moreover, the evaluation or screening of ceramide kinase activators or inhibitors can be conducted, by allowing a sample to be tested such as a synthesized compound or an extract from a microorganism culture or the like to be brought together, and determining whether the sample to be tested activates or inhibits the ceramide kinase activity of the protein of the present invention, in the above-mentioned ceramide kinase activity detection method. For example, the amount of a substrate specifically phosphorylated by the protein in the presence of the compound during substrate phosphorylation reaction (referred to as "a") is compared with the amount of the substrate specifically phosphorylated by the protein in the absence of the compound (referred to as "b"). If a is larger than b, the compound can be determined to possess an activity of activating ceramide kinase. On the contrary, if a is smaller than b, the compound can be determined to possess an activity of inhibiting ceramide kinase. Especially, a substance which strongly and specifically activates the ceramide kinase activity of the protein of the present invention, but does not influence the activity of other phosphorylation enzymes (kinases) can be expected to have a pharmaceutical effect as a ceramide kinase specific activator in the various above-mentioned diseases (various inflammatory disorders, HIV infection, type 2 diabetes mellitus, obesity, septicemia, arteriosclerosis, or the like). On the other hand, a substance which strongly and specifically inhibits the ceramide kinase activity of the protein of the present invention, but does not influence the activity of other phosphorylation enzymes (kinases) can be expected to have a pharmaceutical effect as a ceramide kinase specific

inhibitor for the above-mentioned uses (improvement in the treatment effect for the radiotherapy and chemotherapy of cancer or the like).

[0069] An example of an antibody which specifically binds to the protein of the present invention can be a monoclonal antibody which specifically binds to the protein of the present invention, which can be obtained by the following method.

[0070] Preparation of a monoclonal antibody generally requires the following steps:

- (a) purification of a biomacromolecule for use as the antigen;
- (b) preparation of antibody producing cells, after immunizing an animal using injections of the antigen, bleeding the animal and assaying the antibody titer, in order to determine when the spleen is removed;
- (c) preparation of myeloma cells;
- (d) fusing the antibody producing cells with myeloma cells;
- (e) selecting a hybridoma producing the desired antibody;
- (f) preparing a single cell clone (cloning);
- (g) optionally, culturing the hybridoma cells, or growing animals wherein the hybridoma cells have been transplanted, for large scale preparation of the monoclonal antibody; and
- (h) testing the biological activities and the recognition specificity, or assaying properties as a marker reagent, of the monoclonal antibody thus prepared.

[0071] The method for the preparation of a monoclonal antibody is described below in more detail, in line with the above described steps. However, the method for preparing the antibody is not limited thereto. Antibody producing cells other than spleen cells and myeloma cells can also be used.

(a) Purification of antigen

[0072] The proteins of the present invention prepared as described above or a part thereof can be used as an antigen. Furthermore, since the primary structure of the protein of the present invention is disclosed in the present invention, a partial peptide thereof can be chemically synthesized by a method well-known to the person skilled in the art, and used as the antigen.

(b) Preparation of antibody producing cells

[0073] The antigen produced in step (a) is mixed with an adjuvant such as Freund's complete and incomplete adjuvant, or supplementing agent such as potassium alum, and an experimental animal is administrated with said antigen as an immunogen. The most preferable experimental animal for use is a mouse, without being limited thereto.

[0074] Suitable administration routes for immunizing the mouse include the subcutaneous, intraperitoneal, intravenous, intradermal and intramuscular injection routes, with subcutaneous and intraperitoneal injections being preferred.

[0075] Immunization can be done once, or several times, repeatedly with appropriate intervals (preferably 1 to 5 weeks per interval). Immunized animals are monitored for antibody titer in their sera, and an animal exhibiting a sufficiently high antibody titer is selected as the source of antibody producing cells. Selection of an animal exhibiting a high titer allows the subsequent process to be more efficient. Cells for the subsequent fusion are generally harvested from the animal 3 to 5 days after the final immunization.

[0076] Methods for assaying antibody titer include various well known techniques such as radioimmunoassay (hereinafter, referred to as RIA), enzyme-linked immunosorbent assay (hereinafter, referred to as ELISA), fluorescent antibody assay and passive hemagglutination assay, with RIA and ELISA more preferred for the detection sensitivity, the rapidity, the accuracy, and the potential for automation.

[0077] Determination of antibody titer can be performed, for example, by ELISA, as follows. First, purified or partially purified antigen is adsorbed onto the surface of a solid phase, such as a 96-well ELISA plate, followed by blocking any remaining surface wherein antigen is not bound, with a protein unrelated to the antigen such as bovine serum albumin (hereinafter referred to as BSA). After washing, the well surfaces are contacted with a sample diluted stepwise as the first antibody (for example, mouse serum) to enable binding of the monoclonal antibody in the samples to the antigen. An enzyme-labeled anti-mouse antibody as the secondary antibody, is added to be bound to the mouse antibody. After washing, the substrate for the enzyme is added, and antibody titer can then be calculated by measuring the absorbance change due to color development which is caused by the decomposition of the substrate or the like.

(c) Preparation of myeloma cells

[0078] In general, cells from established mouse cell lines serve as the source of myeloma cells, for example, 8-azaguanine resistant mouse (BALB/c)-derived myeloma strains P3X63Ag8U.1 (P3-U1) [Yelton, D. E., et al., Current Topics

in Microbiology and Immunology, 81, 1-7, (1978)], P3/NSI/1-Ag4-1(NS-1) [Kohler, G., et al., European J. Immunology, 6, 511-519 (1976)], Sp2/0-Ag14 (SP-2) [Shulman, M., et al., Nature, 278, 269-270 (1978)], P3X63Ag8.653 (653) [Keamey, J. F., et al., J. Immunology, 123, 1548-1550 (1979)] and P3X63Ag8 (X63) [Horibata, K. and Hams, A. W., Nature, 258, 495-497 (1975)]. The cell lines are subcultured in an appropriate medium such as 8-azaguanine containing medium [RPMI-1640 medium supplemented with glutamine, 2-mercaptoethanol, gentamicin, fetal calf serum (hereinafter referred to as FCS), and 8-azaguanine], Iscove's Modified Dulbecco's Medium (hereinafter referred to as IMDM) or Dulbecco's Modified Eagle Medium (hereinafter referred to as DMEM). The cells are then transferred to a normal medium such as ASF104 medium (Ajinomoto, K. K.) containing 10% FCS, 3 to 4 days prior to cell fusion, and maintained so that at least 2×10^7 cells are available just on the day of cell fusion.

(d) Cell fusion

[0079] The antibody producing cells to be used are plasma cells and lymphocytes which are the precursor cells thereof, which can be obtained from any part of an individual. Typically, they can be obtained from spleen, lymph nodes, peripheral blood, or any appropriate combination thereof, and spleen cells are most generally used.

[0080] After the last immunization, tissue wherein antibody producing cells are present, such as the spleen, is removed from mouse exhibiting the predetermined antibody titer, and spleen cells as antibody producing cells are prepared. The currently most favorable technique for fusing the spleen cells with the myeloma cells obtained in step (c), is a method using polyethylene glycol which shows relatively low cytotoxicity, and the procedures thereof are simple. An example of this technique is as follows.

[0081] The spleen cells and myeloma cells are washed well with serum-free medium (such as RPMI 1640) or phosphate buffer saline (hereinafter referred to as PBS), and then mixed, so that the ratio of the number of spleen cells to that of myeloma cells is approximately between 5 : 1 and 10:1, and then centrifuged. After the supernatant is discarded and the pelleted cells are sufficiently dispersed, 1 ml of serum-free medium containing 50% (w/v) polyethylene glycol (m.w. 1,000 to 4,000) is added thereto dropwise with mixing. Subsequently, 10 ml of serum-free medium is slowly added and then centrifuged. The supernatant is discarded again, and the pelleted cells are suspended in an appropriate amount of a normal medium containing hypoxanthine - aminopterin - thymidine (hereinafter referred to as "HAT") solution and mouse interleukin-2 (hereinafter referred to as IL-2). The suspension is then dispensed into the wells of culture plates (also referred herein simply as "plates") and incubated in the presence of 5% CO₂ at 37 °C for about 2 weeks, with the supplementary addition of HAT medium as appropriate.

(e) Selection of hybridomas

[0082] When the myeloma cell as mentioned above is a strain resistant to 8-azaguanine, i.e., it is deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRT), any unfused myeloma cells and any myeloma-myeloma fusions are unable to survive in the HAT medium. On the other hand, fusions of antibody producing cells with each other, as well as hybridomas of antibody producing cells with myeloma cells can survive, but the former only having a limited lifetime. Accordingly, continuous culture in HAT medium results in the survival of only the hybridomas wherein an antibody producing cell and a myeloma cell are fused, and the hybridoma can be selected.

[0083] The resulting hybridomas grown up into colonies are then transferred into HAT medium lacking aminopterin (hereinafter referred to as HT medium). Thereafter, for example, an aliquot of the conditioned medium is collected to determine antibody titer using ELISA.

(f) Cloning

[0084] The hybridoma which is revealed to produce a specific antibody by measuring the antibody titer according to a method similar to that described in the step (b), is then transferred to another plate for cloning. Suitable cloning methods include: the limiting dilution method wherein hybridomas are diluted to be one cell per well of a plate and then cultured; the soft agar method wherein colonies are recovered after culturing in soft agar medium; the method of using a micromanipulator to separate a single cell for culture; and "sort-a-clone" wherein a single cell is separated by a cell sorter. The limiting dilution method is simple and is commonly used.

[0085] The cloning procedure according to, for example, the limiting dilution method is repeated 2 to 4 times on each well wherein the antibody titer is detected, and the clones exhibiting stable antibody titers are selected as the monoclonal antibody producing hybridomas of the present invention.

(g) Preparation of monoclonal antibody through the culture of the hybridoma:

[0086] The hybridoma obtained by the cloning is then cultured in normal medium which is replaced with HT medium.

Large-scale culture can be performed by rotating culture using large culture bottles, or by spinner culture. The supernatant from the large-scale culture is applied to be purified by a suitable method, such as gel filtration, which is well known to those skilled in the art, and a monoclonal antibody specifically binding to the protein of the present invention can be obtained. The hybridoma may also be grown intraperitoneally in a mouse having the same phyletic lineage such as BALB/c mouse, or in Nu/Nu mouse, to obtain ascites containing a large amount of the monoclonal antibody of the present invention. Easier purification can be conducted through the use of commercially available monoclonal antibody purification kits (for example, MAbTrap GII Kit; Pharmacia).

[0087] The monoclonal antibody prepared as mentioned above has high antigen specificity to the protein of the present invention.

(h) Assay for monoclonal antibody

[0088] Determination of the isotype and the subclass of the monoclonal antibody obtained can be performed as follows. Suitable identification methods include the Ouchterlony method, ELISA and RIA. The Ouchterlony method is simple, but it is necessary to concentrate the solution when the concentration thereof is low. When ELISA or RIA is used, the conditioned medium can be reacted directly with an antigen adsorbed on a solid phase and further can be reacted with secondary antibodies having specificity for the various immunoglobulin isotypes and subclasses, and then the isotype and subclass of the monoclonal antibody can be identified. Commercially available kits for identification such as a Mouse Typer Kit (manufactured by BioRad) can be used with simpler methods.

[0089] Furthermore, the quantification of protein can be performed according to Folin-Lowry's method, or by calculation based on the absorbance at 280 nm [$1.4 \text{ (OD 280)} = \text{Immunoglobulin } 1 \text{ mg/ml}$].

[0090] The monoclonal antibody thus obtained can be used for detecting, separating and purifying the protein of the present invention based on its specificity.

[0091] The polynucleotide comprising the nucleotide sequence which encodes the protein of the present invention can be used for gene therapy of diseases (various inflammatory disorders, HIV infection, type 2 diabetes mellitus, obesity, septicemia, arteriosclerosis, or the like) which are effectively treated or prevented by ceramide kinase activity of the protein. In said gene therapy, for example, the polynucleotide comprising the nucleotide sequence which encodes the protein of the present invention is inserted into a virus vector, and a patient is infected with the virus (which has been detoxicated) having the recombinant virus vector. Since the protein of the present invention is produced and ceramide kinase activity is exhibited in the patient body, the symptoms can be improved, or the progress thereof can be attenuated in the above-mentioned disorder.

[0092] As a method for introducing the gene therapeutic agent into cells, either a method for introducing the gene using a virus vector or a non-viral method for introducing the gene can be adopted (Nikkei Science, April, 1994, 20-45; Jikkenigaku Zoukan, 12(15)(1994); Jikkenigaku Bessatsu, "Idenshichiryō no Kisogijyū", Yodosha, (1996)).

[0093] Examples of a method for introducing a gene using a virus vector can be the method comprising inserting DNA encoding TR4 or variant TR4 into a DNA virus or RNA virus such as a retrovirus, adenovirus, adenovirus related virus, Herpesvirus, vaccinia virus, poxvirus, poliomyelitis virus, and sindbis virus or the like. Among these, a method using retrovirus, adenovirus, adenovirus related virus and vaccinia virus is especially preferable. Examples of non-viral methods include the method comprising administering an expression plasmid directly into muscle (DNA vaccine method), the liposome method, the lipofectin method, the microinjection method, the calcium phosphate method, the electroporation method, or the like, and the DNA vaccine method and the liposome method are preferable.

[0094] A gene therapeutic agent can be effective as a medicament if it is introduced by an in vivo method comprising introducing DNA directly into the body or by an ex vivo method wherein some kinds of cells are taken out from a human, and DNA is introduced thereinto outside the body, and then the cells are returned to the body (Nikkei Science, April 1994, 20-45; Gekkanyakuji, 36(1), 23-48 (1994); Jikkenigaku Zoukan, 12 (15), (1994)).

[0095] For example, when a gene therapeutic agent is administered to a patient by the in vivo method, it is done through a suitable route such as intravenous, intraarterial, hypodermic, intradermic and intramuscular or the like, depending on the disease or the symptom or the like. Moreover, while said gene therapeutic agent is generally formulated as an injection or the like when it is administered by the in vivo method, conventional carriers can be added thereto if necessary. Moreover, when it is formulated in the form of a liposome or membrane-fusion liposome (Sendai-virus liposome or the like), it can be formulated as a liposome preparation such as a suspended agent, cryogen, and cryogen for centrifugation and subsequent concentration or the like.

[0096] A nucleotide sequence complementary to a partial sequence of the nucleotide sequence shown in SEQ ID No. 1 of the Sequencing Listing can be used for so-called anti sense treatment. An antisense molecule may be used as DNA which usually consists of a 15 or 30 mer complementary to a part of the nucleotide sequence shown in SEQ ID No. 1 of the Sequencing Listing, or a stable DNA derivative such as a phosphorothioate, methyl phosphonate, or a morpholino derivative or the like, or a stable RNA derivative such as 2'-O-alkyl RNA. Such an antisense molecule can be introduced into a cell by a method well known in the technical field of the present invention, such as microinjection,

liposome capsulation, or expression using a vector having an antisense sequence or the like. In radiotherapy and chemotherapy of cancer, for example, the therapeutic efficacy can be expected to be improved when the activity of the protein encoded by the nucleotide sequence shown in the nucleotide numbers 124 to 1734 of SEQ ID No. 1 of the Sequence Listing is reduced by the antisense therapy.

[0097] A composition useful as a medicament containing the above-mentioned antisense oligonucleotide may be manufactured according to well-known methods such as mixing with a pharmaceutically acceptable carrier. Examples of such carriers and manufacture methods are described in Pharmaceutical Sciences by Remington. A sufficient amount of the medicament for treating hyperlipidemia, wherein the expression of the gene containing the nucleotide sequence shown in the nucleotide numbers 124 to 1734 of SEQ ID No. 1 or the activity of the gene product is found to be abnormal, is administered to each individual. The effective dose may be varied due to various factors such as conditions, weight, sex, and age, and due to difference in the administration method such as hypodermic, local, oral and intramuscular. For example, it can be administered at 0.02 to 0.2 mg/kg/hour for 2 hours when it is done by the intravenous injection, and at 1 to 200 mg/m²/day in the case of hypodermic administration.

[Best Mode of Carrying Out the Invention]

[0098] The present invention is explained below in more detail with reference to examples, but the present invention is not limited thereto. In addition, in the following examples, each operation by genetic manipulation was conducted according to a method described in 1989 "Molecular Cloning" [Sambrook, J., Fritsch, E.F. and Maniatis, T. work, and Cold Spring Harbor Laboratory Press], unless otherwise especially indicated. Alternatively, if a commercially available reagent and a commercially available kit were used according to the directions thereof.

[Example 1] cDNA cloning

1) Search for cDNA clone having low homology to mouse sphingosine kinase 1 and analysis of a nucleotide sequence

[0099] Homology search was performed by using the algorithm of tblastn to the dbEST database of NCBI based on the known amino acid sequence of mouse sphingosine kinase 1, and an EST clone (GenBank accession number AA355581) which shares the homology with mouse sphingosine kinase 1 was found.

[0100] In order to obtain a cDNA clone which encodes the nucleotide sequence of this EST clone, library screening was performed on the basis of the method described below using a probe produced by PCR.

2) Amplification of the cDNA fragment by PCR

[0101] The following two oligonucleotide primers based on the EST clone AA 355581 were synthesized:

5'-tcaccactgacatcatcgttactgaacatgcta-3' (cerk1 : SEQ ID No. 3 of the Sequencing Listing);

and

5'-caacgatatgcagcgccgaggtttctgcgtcgtg-3' (cerka1 : SEQ ID No. 4 of the Sequencing Listing).

[0102] Subsequently, PCR was performed with the LA PCR kit version 2.1 (Takara Shuzo Co., Ltd., Japan) by using a commercially available cDNA library as a template. Namely, 50 µl of reaction mixture consisting of 5 µl of cDNA library (Marathon-Ready human leukemia (manufactured by Clontech corporation)), 1 x LA PCR buffer solution containing 0.4 µM each of oligonucleotide primer (cerk1 and cerka1), 400 µM each of dATP, dGTP, dCTP and dTTP, 2.5 mM magnesium chloride and 0.05 units of LA Taq DNA polymerase (Included in the kit) were prepared. First, the reaction mixture was heated at 94°C for 2 minutes, after that a cycle consisting of heating at 94°C for 1 minute, at 60°C for 1 minute and at 72°C for 2 minutes, was repeated 30 times. And then, the reaction solution was heated at 72°C for 10 minutes. Those heating steps were performed by using Takara PCR thermal cycler MP (manufactured by Takara Shuzo Co., Ltd., Japan). As a result of analyzing this reaction mixture by 1% agarose gel electrophoresis, a band having a size near 300bp which the desired DNA fragment would have was observed. The place of the gel

containing this band was cut out, and the DNA fragment in the band was collected from the piece by using a kit for extraction (QIA Quick Gel Extraction Kit manufactured by Qiagen). The obtained DNA fragment was inserted in a pCR2.1 vector (inserted with a TA cloning Kit for Eukaryotes manufactured by Invitrogen Corporation) according to the T/A cloning process (Clark and J. M. et al. (1988) Nucleic Acid Res. 16: 9677-9688), and was introduced into the Escherichia coli TOP10F' strain (attached to TA cloning Kit for Eukaryotes). The plasmid DNA pCR2.1-CERKM was extracted from the obtained transformant, and the nucleotide sequence was determined for all the nucleotide sequences of cDNA inserted according to the dideoxy nucleotide chain termination method. Consequently, the obtained nucleotide sequence was that encoding a part of the nucleotide sequence of the above-mentioned EST clone AA 355581 (nucleotide numbers 611-910 of SEQ ID No. 1 of the Sequencing Listing).

3) Preparation of a filter for plaque hybridization

[0103] Library screening was performed by using a commercially available cDNA library (Lambda ZAP II library manufactured by Stratagene corporation).

[0104] First, the titer of a Lambda ZAP II library was determined by the method described below. The Escherichia coli XL-1 Blue MRF' strain was cultured at 37 °C in LB culture medium (a culture medium wherein 10 g of sodium chloride, 10 g of bactotrypton, and 5 g of yeast extract were dissolved in 1 l of water and the pH was adjusted to 7.0) containing 10 mM of magnesium sulfate and 0.2 % of maltose. Escherichia coli cells were collected by centrifugation at the logarithmic phase of the growth, and 10 mM magnesium sulfate solution added thereto, and then suspended so that the absorbance (OD 600) at 600 nm was 0.5. The phage containing solution was diluted to 10^4 to 10^7 times with TE buffer solution, and 1 μ l of each diluent was mixed with 200 μ l of the Escherichia coli suspension, and incubated at 37 °C for 15 minutes, and the soft-agar culture medium [LB culture medium (a culture medium wherein 10 g of sodium chloride, 10 g of bactotrypton, and 5 g of yeast extract were dissolved in 1 l of water and the pH was adjusted to 7.0) wherein 0.7 % of agar was added.] preheated at 48°C was added, and then inoculated on a sterilized plastics laboratory dish. After incubation at 37°C for 6 to 8 hours, the titer was calculated by counting the plaques. The resulting titer of the primary library was 4.6×10^8 plaque forming units (hereinafter referred to as "pfu").

[0105] Since primary libraries are generally unstable, said primary library consisting of 1×10^8 pfu was again used to infect Escherichia coli, and amplified by the same method as described above, and then was collected, following this, the Lambda ZAP II library was obtained.

[0106] DNA from 5×10^8 plaques among the Lambda ZAP II libraries was fixed on a nitrocellulose filter (manufactured by Stratagene corporation). That is, the Escherichia coli infected with the phage having a cDNA library was spread so that 5×10^4 plaques per plate with a diameter of 15 cm might be formed. The nitrocellulose filter was put on the plate, and was penetrated at three points on a plate with a needle of 18G for identifying the positions thereof later. The plaques were transferred by leaving it for 2 minutes at room temperature, and then the filter was removed, and soaked in an alkali solution (0.5 M sodium hydroxide, 1.5 N sodium chloride) for 2 minutes, and then soaked in a neutralization solution (1.5 M sodium chloride, 0.5 M Tris-hydrochloric acid (pH 8.0)) for 5 minutes, and further soaked in a washing solution containing 2 x SSC and 0.2 M Tris-hydrochloric acid (pH 7.5) for 30 seconds, and subsequently air-dried completely at room temperature for 2 hours. After air drying, the filter was baked at 80°C for 2 hours in order to immobilize the plaques.

4) Preparation of probe and hybridization

[0107] The plasmid pCR2.1-CERKM obtained by the above 2) was digested with a restriction enzyme, EcoRI. The resultant inserted DNA fragment (300 bp) was labeled with 32 P by using a DNA labeling kit (Random Primer Labeling System, manufactured by Gibco BRL: Feinberg, A. P. and Vogelstein, B. (1983) Anal. Biochem. 132, 6). Then, the unincorporated nucleotides were removed by using a micro spin column (Probe Quant G-50 Micro Column, manufactured by Pharmacia) which was filled with a gel filtration resin.

[0108] On the other hand, the nitrocellulose filter wherein the plaques were transferred as prepared in the above 3) was incubated at 37 °C for 2 hour in a solution containing 50 % formamide, 5 x SSC, 5 x Denhardt solution, 0.1 % SDS and 100 μ g/ml denatured salmon sperm DNA (prehybridization). After then, the probe labeled with 32 P was added to be 1×10^6 cpm/filter, and incubated at 37 °C for 12 to 18 hours (hybridization). Then, the filter was washed in a solution containing 1 X SSC, 0.1% SDS at 37 °C for 20 minutes, and then washed in a solution containing 0.1 X SSC, 0.1 % SDS at 60°C for one hour. Then, the filter was subjected to autoradiography.

[0109] Consequently, 12 positive plaques were identified at primary screening. After picking up those plaques from the plate and repeating the above-mentioned screening operation for each plaque, seven positive clones were obtained. Escherichia coli SOLR strain was coinfectd with each positive clone and with the helper phage (ExAssist which was attached to the Lambda ZAP II Library manufactured by Stratagene corporation), and pBluescript phagemid vector containing the desired cDNA was cut out. The transformed Escherichia coli strain carrying the plasmid wherein the

desired cDNA was inserted in the pBluescript phage vector was obtained by the above-mentioned operation. These phage DNA were digested with a restriction enzyme, EcoRI, and subjected to polyacrylamide gel electrophoresis, and the length of the desired cDNA was determined. As a result, three plasmids (pBK-29, pBK-5, and pBK-33) of which the length of inserted cDNAs were about 1.5 kbps, about 3.5 kbps, and about 4.4 kbps respectively were obtained.

5) Determination of nucleotide sequence

[0110] All the nucleotide sequences of cDNA inserted in plasmids pBK-29, pBK-5, and pBK-33 obtained by the above 4), were determined by the dideoxy nucleotide chain termination method. In addition, parts of the sequences were analyzed by using full automatic DNA sequence analysis apparatus (model 373A, manufactured by Perkin Elmer Japan Applied Biosystems corporation). Consequently, cDNA inserted in pBK-33 had the nucleotide sequence which consists of 4463 bp(s) (SEQ ID No. 1 of the Sequencing Listing) including all of the sequences of the inserted cDNAs of pBK-29 and pBK-5. Furthermore, this nucleotide sequence and the amino acid sequence encoded by the open reading frame (hereinafter referred to as "ORF") included in this nucleotide sequence (amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing) were subjected to homology search with DNA databases, GenBank and EMBL, and a protein database, SWISS-PLOT. As a result of the homology search, there were no proteins having known function which were especially highly homologous to the amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing, and thus it became clear that it is a novel protein. Moreover, the sequence homology between the amino acid sequence which is shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing and the amino acid sequence covering the full length of the human sphingosine kinase 1 or 2 was only 29%, but the conserved domain thereof was highly homologous to those of sphingosine kinases beyond species (See T. Kohama et al. (1998) J. Biol. Chem. 273. 23722-23728). Furthermore, when a motif search was performed, it was suggested that it possessed a PH domain (See A. D. Ma & C. S. Abrams (1999) Thromb. Haemost. 82,399 to 406) and a diacylglycerol kinase domain (See F. Sakana & H. Kanoh (1997) Int. J. Biochem. Cell Biol. 29, 1139-1143). The cDNA which encoded the novel protein thus obtained was named hCERK1.

[Example 2] Expression of the recombinant protein

1) Production of an expression vector

[0111] The hCERK1 obtained in Example 1 was expressed using a vertebrate cell expression system, and expressed protein was obtained. First, a eukaryote expression vector for expressing cDNA which has the cDNA encoding the amino acid numbers 1-537 of the amino acid sequence shown in SEQ ID No. 2 of the Sequencing Listing at the down stream of a cytomegalovirus promoter was constructed.

[0112] In order to construct the above-mentioned vector, pBK-33 obtained in 4) of Example 1 was digested with a restriction enzyme, SacII, and a fragment of about 2.3 kbp(s) including the inserted cDNA was isolated. On the other hand, the vector pCR3.1 (manufactured by Invitrogen) for expression in eukaryotes was digested with a restriction enzyme, EcoRI, and dephosphorylated with alkaline phosphatase. The above-mentioned 2.3 kbp fragment and pCR3.1 vector were blunt-ended by using a DNA Blunting Kit (Manufactured by Takara Shuzo Co., Ltd., Japan), and connected to each other by a reaction using T4 DNA ligase (Manufactured by Takara Shuzo Co., Ltd., Japan), and then introduced into the Escherichia coli TOP10F' strain. The plasmid DNAPCR3.1-CERK1 was extracted from the obtained transformant, and the full nucleotide sequence of the inserted cDNA was confirmed by the dideoxy chain termination method.

[0113] The transformed Escherichia coli strain E.coli pCR3.1-CERK1 SANK 70300 carrying this plasmid pCR3.1-CERK1 for expression was internationally deposited on June 2, 2000 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology at 1-1-3, Higashi-cho, Tsukuba-shi, Ibaraki-ken, Japan, and the deposition number FERM BP-7184 was given.

2) Expression in animal cells

[0114] In order to examine whether the protein of the present invention has ceramide kinase activity, the human embryo kidney cell HEK293 (ATCC CRL-1573) was transfected with the expression vector pCR3.1-CERK1 obtained above. That is, after putting 6×10^5 HEK293 cells per well into a polylysine-coated 6-well plate for tissue culture (manufactured by Iwaki Glass) and incubating at 37 °C for 24 hours, they were transfected with one μ g of pCR3.1-CERK1 by using a transfection reagent (Lipofectamin plus, manufactured by Life technology) according to the directions attached thereto. After the operation for the transfection was finished, cells were cultured at 37 °C for one day and the conditioned medium was removed. Then, the cells were collected by using buffer solution A (10 % glycerol, 1 mM dithiothreitol, 1 mM EDTA, 1 mM sodium vanadate, protease inhibitor (Complete™, manufactured by Boehringer Mannheim), a 200 mM Hepes buffer solution, pH 7.0). By ultrasonication with a probe-type sonicator (Cell Disrupter

200, manufactured by Branson), the collected cells were broken into pieces, and the resulting cell lysate was diluted and then used for measurement of enzyme activity as shown in Example 3.

[0115] Since the pCR3.1 expression vector has the neo gene which functions as a marker for antibiotics G418 resistance, G418 resistant colonies were selected by culturing HEK293 cells after transfection of pCR3.1-CERK1 in the presence of G418. Thus, the transformed cell which produces the protein of the present invention stably was obtained.

[Example 3] Measurement of ceramide kinase activity

[0116] Measurement of ceramide kinase activity was performed according to the method described below using the cell lysate containing the protein of the present invention which was prepared in Example 2 above, by using [32 P]- γ -ATP and various ceramides as a substrate.

[0117] Specifically, 10 μ l of 1 mM C_6 -ceramide prepared by using BSA solution (4 mg/ml) and 10 μ l of a mixture of 100 mM magnesium chloride and 2 mM of radiolabeled [32 P]-gamma-ATP (manufactured by NEN) were added to 180 μ l of buffer B [1 mM dithiothreitol, 1 mM EDTA, 1 mM sodium vanadate, protease inhibitor (Complete TM, manufactured by Boehringer Mannheim), 1 mM calcium chloride, a 200 mM HEPES buffer solution, pH 7.0] which further contains the protein of the present invention prepared in Example 2, and then incubated at 37 °C for 20 minutes to conduct the ceramide kinase reaction. Next, after stopping the reaction by adding 20 μ l of 1 N hydrochloric acid, 800 μ l (100:200:1, v/v) of chloroform : methanol : concentrated hydrochloric acid, 250 μ l of 2.5 M potassium chloride, and 250 μ l of chloroform were added thereto and extracted. The resulting extract was subjected to centrifugation at 2000 x g, and the obtained lower layer (chloroform phase) was developed and analyzed on TLC. In addition, as the developing solvent used for TLC, butanol ethanol water acetic acid (80:20:10:20) was found to be preferable. The ceramide kinase activity was determined by quantifying the radioactivity of the spot corresponding to ceramide-1-phosphate (hereinafter referred to as "Cer-1-P") with an imaging analyzer (BAS2000, Fuji film) as a product (identified as the spot which appears stronger with the extract of the reaction using the sample derived from the cell which was transformed with pCR3.1-CERK1 than that which appeared with the extract of the negative-control reaction mixture using a sample derived from the cell which was transformed with an empty vector pCR3.1) in the above TLC.

[0118] As a result of measuring by the above-mentioned method, the ceramide kinase activity of the enzyme solution which contains the protein of the present invention obtained in Example 2 was 1280 pmol/min/mg when the substrate was C_6 -ceramide. The K_m value over C_6 -ceramide was 7 μ M. In addition, the ceramide kinase activity measured similarly for the cell lysate obtained when HEK293 cell was transfected with only pCR3.1 vector as negative-reaction control was 7 pmol/min/mg.

[0119] And, it was more preferable to micellize the ceramide using surface active agents such as an octyl glucoside, when natural type ceramides such as ceramide derived from bovine fetal brain is used as the substrate. That is, a necessary amount of ceramide dissolved in chloroform was dried to be solid under a nitrogen air current, and the buffer solution B which contains 0.2% of octyl glucoside was added thereto, and then subjected to ultrasonication, and finally 100 μ M ceramide solution was provided. 90 μ l of the mixture of buffer solution B containing the enzyme solution and 10 μ l of the mixture consisting of 100 mM magnesium chloride and 2 mM radio-labeled [32 P]- γ -ATP were added to 100 μ l of said substrate solution, and then incubated at 37 °C for 20 minutes to perform the ceramide kinase reaction. Extraction of Cer-1-P was conducted by a similar procedure to the above-mentioned. The ceramide kinase activity of the enzyme solution containing the protein of the present invention measured by this method was 200 pmol/min/mg when the substrate was ceramide derived from bovine fetal brain.

[0120] Then, C_6 -ceramide was used as a substrate and the optimum assay conditions for the protein of the present invention were examined. As a result, the optimum pH of the protein of the present invention was 7 to 7.5, and was activated by magnesium chloride and calcium chloride. Moreover, this ceramide kinase activity was inhibited by surface active agents such as Triton X-100 and cholic acid, phosphatidylserine, and Tris buffer. Moreover, when the cell lysate wherein the protein of the present invention was expressed was divided into a membrane fraction and a cytoplasmic soluble fraction by centrifugation at 100000 x g after the removal of non-lysed cells through centrifugation at 3000 x g, and then the ceramide kinase activity of each fraction was measured, the stronger ceramide kinase activity was observed in the membrane fraction.

[0121] Until now, ceramide kinase activity has been reported in nerve synaptic vesicles (See S. M. Bajjalieh, et al. (1989) J. Biol. Chem. 264, 14354 -14360), HL-60 cell (See K. A. Dressler, et al. (1990) J. Biol. Chem. 265, 14917-1492), neutrophil leucocytes (See V. T. Hinkovska-Galcheva, et al. (1998) J. Biol. Chem. 273, 33203-33209 reference) etc. As the properties that they shared, it have been pointed out that they are activated by calcium, that they are membrane-binding type, and that the optimum pH is neutral. The ceramide kinase activity of the recombinant protein of the present invention had all of these properties.

[0122] While the protein of the present invention has a diacylglycerol (hereinafter referred to as "DG") kinase domain, it was activated by calcium which does not influence DG kinase (See F. Sakana & H. Kanoh (1997) Int. J. Biochem. Cell Biol. 29, 1139-1143), and was inhibited by phosphatidylserine which is an activator of DG kinase (See H. Kanoh et al.

(1883) J. Biol. Chem. 258, 1767-1774). Namely, it had clearly different properties from those DG kinase has.

[0123] Next, in order to examine the substrate specificity of the protein of the present invention, the phosphorylation activity of HEK293 cells expressing pCR3.1-CERK1 was compared with that of the cells expressing only pCR3.1 vector (the enzyme activity which HEK293 cell has endogenously), by using various lipids as substrates (Table 1).

[Table 1]

Substrate	Phosphorylation activity (pmol/min/mg)		Ratio of activities (pCR3.1-CERK1/pCR3.1)
	Transformed with pCR3.1-CERK1	Transformed with pCR3.1	
C ₆ -ceramide	1280	7	183
Ceramide derived from bovine fetal brain	200	10	20
DG	150	130	1
D-erythro-sphingosine	50	50	1

[0124] The protein of the present invention phosphorylated various ceramides such as C₆-ceramide and ceramide derived from bovine fetal brain, a natural type, with high efficiency. On the other hand, under the optimum assay conditions for the above-mentioned ceramide kinase, it hardly phosphorylated the lipids such as DG and sphingosine. Namely, it has high substrate specificity to ceramides.

[Industrial applicability of the invention]

[0125] As described above, a novel protein having ceramide kinase activity and DNA encoding it are provided in the present invention. Furthermore, the present invention also provides a method for testing a ceramide kinase activator or inhibitor using the protein, and a specific and highly sensitive method for detecting or quantifying ceramide using the protein. The protein of the present invention or DNA encoding it are useful for searching for novel compounds which have a specifically activating or inhibiting activity against ceramide kinase as a medicament for treating neuronal disorder, an anti-inflammatory medicament, a medicament for treating HIV infection, an anti-type 2 diabetes mellitus medicament, an anti-obesity medicament, an anti-septicemia medicament, an anti-arteriosclerosis medicament and an anticancer medicament, and for analyzing the various conditions of the above-mentioned diseases.

SEQUENCE LISTING

5 <110> Sankyo Company, Limited

<120> Ceramide Kinase and DNA Encoding It

10 <130> EPP86264

<150> JP 2000-178039

<151> 2000-06-14

15 <160> 4

<170> PatentIn Ver. 2.0

20 <210> 1

<211> 4463

<212> DNA

25 <213> Homo sapiens

<220>

<221> CDS

30 <222> (124).. (1734)

<400> 1

gcgcgcctc ccgcagcccg ccgcccgcg ccgcgcgcc gggccactgc aggggcccgt 60

35 aacgggtccgg cgcccctcgg cgtccgcgcg ccccagcct ggcggacgag ccggcggcg 120

gag atg ggg gcg acg ggg gcg gcg gag ccg ctg caa tcc gtg ctg tgg 168

40 Met Gly Ala Thr Gly Ala Ala Glu Pro Leu Gln Ser Val Leu Trp

1 5 10 15

gtg aag cag cag cgc tgc gcc gtg agc ctg gag ccc gcg cgg gct ctg 216

45 Val Lys Gln Gln Arg Cys Ala Val Ser Leu Glu Pro Ala Arg Ala Leu

20 25 30

ctg cgc tgg tgg cgg agc ccg ggg ccc gga gcc ggc gcc ccc ggc gcg 264

50 Leu Arg Trp Trp Arg Ser Pro Gly Pro Gly Ala Gly Ala Pro Gly Ala

35 40 45

gat gcc tgc tct gtg cct gta tct gag atc atc gcc gtt gag gaa aca 312

55 Asp Ala Cys Ser Val Pro Val Ser Glu Ile Ile Ala Val Glu Glu Thr

50 55 60

EP 1 291 430 A1

5	gac gtt cac ggg aaa cat caa ggc agt gga aaa tgg cag aaa atg gaa	360
	Asp Val His Gly Lys His Gln Gly Ser Gly Lys Trp Gln Lys Met Glu	
	65 70 75	
10	aag cct tac gct ttt aca gtt cac tgt gta aag aga gca cga cgg cac	408
	Lys Pro Tyr Ala Phe Thr Val His Cys Val Lys Arg Ala Arg Arg His	
	80 85 90 95	
15	cgc tgg aag tgg gcg cag gtg act ttc tgg tgt cca gag gag cag ctg	456
	Arg Trp Lys Trp Ala Gln Val Thr Phe Trp Cys Pro Glu Glu Gln Leu	
	100 105 110	
20	tgt cac ttg tgg ctg cag acc ctg cgg gag atg ctg gag aag ctg acg	504
	Cys His Leu Trp Leu Gln Thr Leu Arg Glu Met Leu Glu Lys Leu Thr	
	115 120 125	
25	tcc aga cca aag cat tta ctg gta ttt atc aac ccg ttt gga gga aaa	552
	Ser Arg Pro Lys His Leu Leu Val Phe Ile Asn Pro Phe Gly Gly Lys	
	130 135 140	
30	gga caa ggc aag cgg ata tat gaa aga aaa gtg gca cca ctg ttc acc	600
	Gly Gln Gly Lys Arg Ile Tyr Glu Arg Lys Val Ala Pro Leu Phe Thr	
	145 150 155	
35	tta gcc tcc atc acc act gac atc atc gtt act gaa cat gct aat cag	648
	Leu Ala Ser Ile Thr Thr Asp Ile Ile Val Thr Glu His Ala Asn Gln	
	160 165 170 175	
40	gcc aag gag act ctg tat gag att aac ata gac aaa tac gac ggc atc	696
	Ala Lys Glu Thr Leu Tyr Glu Ile Asn Ile Asp Lys Tyr Asp Gly Ile	
	180 185 190	
45	gtc tgt gtc ggc gga gat ggt atg ttc agc gag gtg ctg cac ggt ctg	744
	Val Cys Val Gly Gly Asp Gly Met Phe Ser Glu Val Leu His Gly Leu	
	195 200 205	
50	att ggg agg acg cag agg agc gcc ggg gtc gac cag aac cac ccc cgg	792
	Ile Gly Arg Thr Gln Arg Ser Ala Gly Val Asp Gln Asn His Pro Arg	
	210 215 220	
55	gct gtg ctg gtc ccc agt agc ctc cgg att gga atc att ccc gca ggt	840
	Ala Val Leu Val Pro Ser Ser Leu Arg Ile Gly Ile Ile Pro Ala Gly	
	225 230 235	

10

10

EP 1 291 430 A1

5 ggg tct tct gac ctc atc ctc atc cgg aaa tgc tcc aag ttc aat ttt 1416
 Gly Ser Ser Asp Leu Ile Leu Ile Arg Lys Cys Ser Lys Phe Asn Phe
 420 425 430

10 ctg aga ttt ctc atc agg cac acc aac cag cag gac cag ttt gac ttc 1464
 Leu Arg Phe Leu Ile Arg His Thr Asn Gln Gln Asp Gln Phe Asp Phe
 435 440 445

15 act ttt gtt gaa gtt tat cgc gtc aag aaa ttc cag ttt acg tgc aag 1512
 Thr Phe Val Glu Val Tyr Arg Val Lys Lys Phe Gln Phe Thr Ser Lys
 450 455 460

20 cac atg gag gat gag gac agc gac ctc aag gag ggg ggg aag aag cgc 1560
 His Met Glu Asp Glu Asp Ser Asp Leu Lys Glu Gly Gly Lys Lys Arg
 465 470 475

25 ttt ggg cac att tgc agc agc cac ccc tcc tgc tgc tgc acc gtc tcc 1608
 Phe Gly His Ile Cys Ser Ser His Pro Ser Cys Cys Cys Thr Val Ser
 480 485 490 495

30 aac agc tcc tgg aac tgc gat ggg gag gtc ctg cac agc cct gcc atc 1656
 Asn Ser Ser Trp Asn Cys Asp Gly Glu Val Leu His Ser Pro Ala Ile
 500 505 510

35 gag gtc aga gtc cac tgc cag ctg gtt cga ctc ttt gca cga gga att 1704
 Glu Val Arg Val His Cys Gln Leu Val Arg Leu Phe Ala Arg Gly Ile
 515 520 525

40 gaa gag aat ccg aag cca gac tca cac agc tgagaagccg gcgtcctgct 1754
 Glu Glu Asn Pro Lys Pro Asp Ser His Ser
 530 535

45 cacaaactgg gaaagtgtga aaactattta agataattat tacagaccaa ttatgttgat 1814
 atatacattt aaatgtagaa atttattttt gatagttaaa tcttgatttt agaagaaaac 1874
 ccttttgtca acaattttgt gtacatattt ggcattttca gttctgtacg catctgcggg 1934

50 ttgcagccca cgccgcttac tctcagcgga tgcagctgct cacttggggg cactggcctc 1994
 ttaggtttta acgatgtcaa cagtgtagtt tagaaaatgg cccgttagtg gctctattgc 2054

55 aataatgtta gggacattat atgatttcca cgcaggtcac accatctggg cctgaggtag 2114

5 cagtgggtca ctttgatcca ctttgcagga cttattctgt aacggtttgt ggccaagtgt 2174
tggaagtgg ttgattatct ttgccttcat ttcaccttcc tottcgttta cggtaggac 2234
10 atcgctgctt gatccttaca atactgtgca actgcaatgc aacgtggccc tgcttcaggt 2294
gatccgcggg aggggcctcc acgccagcgc cgggaaggct gctggggcct ccacacctgc 2354
ctcatcacgg cggcgaggct acgacaatcc ggctgggagc atgaccttg cgtctgttct 2414
15 gggagcacag atgataagct ctggaagctg gcagtgtgta aagcactggc aagtttgta 2474
ctgttaaaat gtcaaatacc aatgctttat atcgacgcga agtgcttaac acagccgggc 2534
20 ttgggggcag tcaggaggaa gctggccatc cgtggaggag gggccggctc tggactccc 2594
caggactcct ctgatgcagg gcctgaagtc tgtacacgtg gtccaaattt gtccttgtct 2654
25 tttcttcaca ctgagttctc tatatttatt gaacatcttg tccttttaag ccagagtagt 2714
gtaaactgcg tctcgatgt ctgtcttttg tgcgaagcc acgatggatc gctggtttcc 2774
30 tctgcagcgc aagggtccg gcgaccagag gattcttccc ggaaaggcat tctgcccgc 2834
ctcccgggg caccctcaa ttgtgtacta cgtccttgtt tagtgtgtat cgtgcccac 2894
35 gtagatgatg tctgtaacgt agttttgttt gaaatatgag aatatcggc ttaaactttg 2954
atctgtaagg agcggggccg tggccgtttg gagcacgctg tagacacgt tctcatgct 3014
40 gccgggtggg ttttcagaa gctcccttag tgatttcatg tttaacaggc agcatccatt 3074
ttcagaattt cctggcattg atttatattt tgaagcatac aggaaacttc tcgtttctc 3134
45 gttagcccc acccagatca ggtgaaaggg cagctttaat ggtggtttt atggaccaca 3194
ttatcagaga gcactgtgca agccaaatgg ttcaataatg aatgaaaatt ctgggtgtaa 3254
50 agagtaaata tgccctggct ctttctacca atgtttgctc ctggttgga agaaaccaa 3314
gatttaagac gggctgctct tccagactgg ctgtgcctgc ctgtgccag caacctntgc 3374
55 agccggcagt gtccctggg tcacgccagg aggtgtggc tgctgtggc cctctggaat 3434

EP 1 291 430 A1

tgtgtcctc acaaagtttc cccaaaaggt tcttctaagc ctttattgtc cctggtaaat 3494
gtttcccggc tgggcgcggt ggctcacgcc tgtaatcca gcactttggg aggcagaggc 3554
gggtggatca cctaaggtca ggagttagg atcagcctgc ccaacatggt gaaacctcgt 3614
ctctactaaa aatacacaac ttagccagtc ttgttggcgc acgcctgtaa tctcagctac 3674
tagggatgct gaggcaggag aatcgctga acccaagaaa gaggtggagg ttgcggtgag 3734
ccaagattgc gccactgcac tccagcctgg gcaacagagg gagactccat cgtccccct 3794
cancacaaa aaaagtttc catacactgg cctgccccaa aaccactaa caattttage 3854
aaaacagtc agccaaagag gaagcatttc atgttcaata agaaaccag ccattccga 3914
tggctggttc ctgagtggct ctggtgatac tctccagcca cctgctgaca ttcagaatct 3974
cagacctcgg ggactgctgt tgcggtaccg tgtgtctgac acctgccagc agccctttgc 4034
tatctgcgcg caggatgggg gtgactgccc agacattccc gctagatagg ctctgatttc 4094
cggggcagcc tttcagatgc ggcagacata caacacctgt acttagagt ttaagggaa 4154
aaaaaaatca gaagtgttg ttagatagta aaaacttagg ataacttaga aaggctagtt 4214
ttagcttcc tttgtgctcc ctggtgcaaa acaattagca gttatgcaat ggacctgatt 4274
ctagtttatt ctaattaaga agtgaggccg ggtttgactt cgttcctgaa tacaatcttg 4334
agtaactggg aaagtctgag tgaaaggatg gcctcattct ctttctaate ttgctggttt 4394
caagattaga aatggcatt atttgatctg aaatgtttga gaagacacga ataaagctcg 4454
tgccgaatt 4463

```
<210> 2
<211> 537
<212> PRT
<213> Homo sapiens
```

<400> 2

EP 1 291 430 A1

5	Met Gly Ala Thr Gly Ala Ala Glu Pro Leu Gln Ser Val Leu Trp Val	1	5	10	15
10	Lys Gln Gln Arg Cys Ala Val Ser Leu Glu Pro Ala Arg Ala Leu Leu	20	25	30	
15	Arg Trp Trp Arg Ser Pro Gly Pro Gly Ala Gly Ala Pro Gly Ala Asp	35	40	45	
20	Ala Cys Ser Val Pro Val Ser Glu Ile Ile Ala Val Glu Glu Thr Asp	50	55	60	
25	Val His Gly Lys His Gln Gly Ser Gly Lys Trp Gln Lys Met Glu Lys	65	70	75	80
30	Pro Tyr Ala Phe Thr Val His Cys Val Lys Arg Ala Arg Arg His Arg	85	90	95	
35	Trp Lys Trp Ala Gln Val Thr Phe Trp Cys Pro Glu Glu Gln Leu Cys	100	105	110	
40	His Leu Trp Leu Gln Thr Leu Arg Glu Met Leu Glu Lys Leu Thr Ser	115	120	125	
45	Arg Pro Lys His Leu Leu Val Phe Ile Asn Pro Phe Gly Gly Lys Gly	130	135	140	
50	Gln Gly Lys Arg Ile Tyr Glu Arg Lys Val Ala Pro Leu Phe Thr Leu	145	150	155	160
55	Ala Ser Ile Thr Thr Asp Ile Ile Val Thr Glu His Ala Asn Gln Ala	165	170	175	
	Lys Glu Thr Leu Tyr Glu Ile Asn Ile Asp Lys Tyr Asp Gly Ile Val	180	185	190	
	Cys Val Gly Gly Asp Gly Met Phe Ser Glu Val Leu His Gly Leu Ile	195	200	205	
	Gly Arg Thr Gln Arg Ser Ala Gly Val Asp Gln Asn His Pro Arg Ala	210	215	220	
	Val Leu Val Pro Ser Ser Leu Arg Ile Gly Ile Ile Pro Ala Gly Pro	225	230	235	240

EP 1 291 430 A1

5	Thr Asp Cys Val Cys Tyr Ser Thr Val Gly Thr Ser Asp Ala Glu Thr	245	250	255
10	Ser Ala Leu His Ile Val Val Gly Asp Ser Leu Ala Met Asp Val Ser	260	265	270
15	Ser Val His His Asn Ser Thr Leu Leu Arg Tyr Ser Val Ser Leu Leu	275	280	285
20	Gly Tyr Gly Phe Tyr Gly Asp Ile Ile Lys Asp Ser Glu Lys Lys Arg	290	295	300
25	Trp Leu Gly Leu Ala Arg Tyr Asp Phe Ser Gly Leu Lys Thr Phe Leu	305	310	315
30	Ser His His Cys Tyr Glu Gly Thr Val Ser Phe Leu Pro Ala Gln His	325	330	335
35	Thr Val Gly Ser Pro Arg Asp Arg Lys Pro Cys Arg Ala Gly Cys Phe	340	345	350
40	Val Cys Arg Gln Ser Lys Gln Gln Leu Glu Glu Glu Gln Lys Lys Ala	355	360	365
45	Leu Tyr Gly Leu Glu Ala Ala Glu Asp Val Glu Glu Trp Gln Val Val	370	375	380
50	Cys Gly Lys Phe Leu Ala Ile Asn Ala Thr Asn Met Ser Cys Ala Cys	385	390	395
55	Arg Arg Ser Pro Arg Gly Leu Ser Pro Ala Ala His Leu Gly Asp Gly	405	410	415
	Ser Ser Asp Leu Ile Leu Ile Arg Lys Cys Ser Lys Phe Asn Phe Leu	420	425	430
	Arg Phe Leu Ile Arg His Thr Asn Gln Gln Asp Gln Phe Asp Phe Thr	435	440	445
	Phe Val Glu Val Tyr Arg Val Lys Lys Phe Gln Phe Thr Ser Lys His	450	455	460
	Met Glu Asp Glu Asp Ser Asp Leu Lys Glu Gly Gly Lys Lys Arg Phe			

EP 1 291 430 A1

465 470 475 480
 5 Gly His Ile Cys Ser Ser His Pro Ser Cys Cys Cys Thr Val Ser Asn
 485 490 495
 10 Ser Ser Trp Asn Cys Asp Gly Glu Val Leu His Ser Pro Ala Ile Glu
 500 505 510
 15 Val Arg Val His Cys Gln Leu Val Arg Leu Phe Ala Arg Gly Ile Glu
 515 520 525
 20 Glu Asn Pro Lys Pro Asp Ser His Ser
 530 535
 25 <210> 3
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: PCR primer to
 amplify a fragment of cDNA encoding human ceramide
 kinase
 35 <400> 3
 tcaccactga catcatcggt actgaacatg cta 33
 40 <210> 4
 <211> 35
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Description of Artificial Sequence: PCR primer to
 amplify a fragment of cDNA encoding human ceramide
 50 kinase
 <400> 4
 55 caacgatatg cagcgccgag gtttctgcgt cgctg 35

Claims

1. A protein having a property of the following I) or II):

- I) a protein which comprises an amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing;
- II) a protein which comprises an amino acid sequence wherein one or more than one amino acids are added, deleted and/or replaced in the amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing, and has ceramide kinase activity.

2. A protein comprising an amino acid sequence shown in the amino acid numbers 1-537 of SEQ ID No. 2 of the Sequencing Listing.

3. A protein encoded by DNA which is inserted in the plasmid carried by a transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184).

4. A DNA which encodes a protein according to any one of Claims 1 to 3.

5. A DNA comprising a nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing.

6. A DNA which hybridizes to a DNA comprising a nucleotide sequence shown in the nucleotide numbers 124-1734 of SEQ ID No. 1 of the Sequencing Listing under stringent conditions, and encodes a protein having ceramide kinase activity.

7. A DNA inserted in the plasmid which is carried by transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184).

8. A recombinant DNA vector comprising DNA of any one of Claims 4 to 7.

9. A recombinant DNA vector according to claim 8, said recombinant DNA vector being carried by transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184).

10. A recombinant DNA vector according to claim 9, said recombinant DNA vector being an expression vector.

11. A host cell transformed with the recombinant DNA vector according to any one of Claims 8 to 10.

12. A host cell according to Claim 11, said host cell being transformed *Escherichia coli* E.coli pCR3.1-CERK1 SANK 70300 (FERM BP-7184).

13. A host cell transformed with the recombinant DNA vector according to Claim 10.

14. A method for producing a protein having ceramide kinase activity wherein a host cell according to Claim 13 is cultured under the conditions in which the protein having ceramide kinase activity can be produced, and subsequently the protein having ceramide kinase activity is collected from the culture.

15. A method for producing the protein according to any one of claims 1 to 5 comprising the following steps (i) to (iii):

- (i) an extract of a material containing the protein according to any one of Claims 1 to 3 dissolved in a solvent which does not contain calmodulin is allowed to adsorb on affinity-chromatography resin having calmodulin as a substituent;
- (ii) the resin of (i) is washed with a solvent which does not contain calmodulin;
- (iii) the protein having ceramide kinase activity is eluted with a solvent containing EGTA or EDTA from the resin washed in the step (ii).

16. A method for testing the ceramide kinase activating or inhibiting effect of a compound or a composition sample, said method comprises the following steps (i) to (iv):

(i) preparing a mixture wherein a protein according to any one of claims 1 to 3, a substrate which can be phosphorylated specifically by the protein and said compound or composition sample are brought together, and a mixture wherein the protein and the substrate are brought together but the compound or composition sample is not added,

(ii) measuring and comparing the amount of the substrate phosphorylated in each of the mixtures prepared in (i).

17. A method according to claim 16, said method being **characterized in that** the substrate which can be phosphorylated specifically by a protein according to any one of claims 1 to 3 is one selected from the group consisting of C₂ ceramide, C₆ ceramide, C₈ ceramide, C₁₆ ceramide, and ceramide derived from bovine fetal brain.

18. A method for detecting or quantifying ceramide in a sample, said method being **characterized in that** a protein according to any one of claims 1 to 3, the sample to be tested, and labeled adenosine 5'-triphosphate are brought together, and then the labeled ceramide is detected or quantified.

19. Use of a protein according to any one of claims 1 to 3 for the production of a kit for detecting or quantifying ceramide.

20. An antibody which specifically binds to a protein according to any one of claims 1 to 3.

21. A pharmaceutical composition comprising a DNA according to any one of Claims 4 to 7 as an active ingredient.

22. A nucleic acid comprising the antisense sequence to a nucleotide sequence consisting of 15 to 30 continuous nucleotides in the nucleotide sequence shown in SEQ ID No.1 of Sequencing Listing.

23. A pharmaceutical composition comprising a nucleic acid according to claim 22.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/04889

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.⁷ C12N15/54, C12N9/12, C12N1/21, C12Q1/48, C07K16/40, A61K31/7125, A61K48/00, A61P3/04, A61P3/10, A61P7/00, A61P25/00, A61P29/00, A61P31/18, A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.⁷ C12N15/54, C12N9/12, C12N1/21, C12Q1/48, C07K16/40, A61K31/7125, A61K48/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
JICST FILE (JOIS), WPI (DIALOG), BIOSIS (DIALOG),
MEDLINE (STN),
EMBL/DBJ/Genbank/PIR/Swissprot/Geneseq

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO, 00/52173, A2 (NPS Allelix Corporation), 08 September, 2000 (08.09.00), Claims; Figs. 7, 9; sequence list, sequence Nos. 7, 9 & AU, 2000-28999, A	1-23
PX	WO, 00/58473, A2 (Curagen Corporation), 05 October, 2000 (05.10.00), Claims; pages 207, 217, 411, 413, 418, 419; sequence list, sequence Nos. 3171, 3172, 4293, 4294 & AU, 2000-37745, A	22-23
A	Gene, Vol. 251 [1], (13 June, 2000), A. J. Melendez et al., "Human sphingosine kinase; molecular cloning, functional characterization and tissue distribution", pages 19 to 26	1-23
A	J. Biol. Chem., Vol. 273 [37], (1998), T. Kohama et al., "Molecular Cloning and functional Characterization of Murine Sphingosine Kinase", pages 23722 to 23728	1-23

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not

considered to be of particular relevance

"E" earlier document but published on or after the international filing

date

"L" document which may throw doubts on priority claim(s) or which is

cited to establish the publication date of another citation or other

special reasons (as specified)

"O" document referring to an oral disclosure, use, exhibition or other

means

"P" document published prior to the international filing date but later

than the priority date claimed

"T" later document published after the international filing date or

priority date and not in conflict with the application but cited to

understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be

considered novel or cannot be considered to involve an inventive

step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be

considered to involve an inventive step when the document is

combined with one or more other such documents, such

combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search
26 June, 2001 (26.06.01)Date of mailing of the international search report
10 July, 2001 (10.07.01)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.